Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew W. Shyjan is active.

Publication


Featured researches published by Andrew W. Shyjan.


Diabetes | 1997

Cloning and Characterization of an Uncoupling Protein Homolog: A Potential Molecular Mediator of Human Thermogenesis

Ruth E. Gimeno; Marlene Dembski; Xun Weng; Nanhua Deng; Andrew W. Shyjan; Carlos J. Gimeno; Francois Iris; Stephen J Ellis; Elizabeth A. Woolf; Louis A. Tartaglia

We have identified a novel cDNA encoding a protein highly homologous to the mammalian brown fat uncoupling protein (UCP). Unlike the known UCP, which is expressed specifically in brown adipose tissue, the UCP homolog (UCPH) mRNA is expressed in a variety of tissues, with predominant expression in human white adipose tissue and skeletal muscle. In the white adipose tissue of ob/ob and db/db mice, the UCPH transcript is induced approximately fivefold relative to lean littermate controls. Expression of murine UCPH in yeast results in growth inhibition under conditions that require aerobic respiration, but does not affect growth under anaerobic conditions. Furthermore, UCPH expression in yeast causes a decrease in the mitochondrial membrane potential, as judged by staining with the potential-sensitive dye DiOC6. These observations suggest that UCPH, like UCP, uncouples oxidative phosphorylation. The possibility that the UCPH protein is an important mediator of human thermogenesis is discussed.


Cancer Research | 2005

Human Splicing Factor SPF45 (RBM17) Confers Broad Multidrug Resistance to Anticancer Drugs When Overexpressed— a Phenotype Partially Reversed By Selective Estrogen Receptor Modulators

William L. Perry; Robert L. Shepard; Janardhan Sampath; Benjamin C. Yaden; William W. Chin; Philip W. Iversen; Shengfang Jin; Andrea Lesoon; Kathryn A. O'Brien; Victoria L. Peek; Mark Rolfe; Andrew W. Shyjan; Michelle Tighe; Mark Williamson; Venkatesh Krishnan; Robert E. Moore; Anne H. Dantzig

The splicing factor SPF45 (RBM17) is frequently overexpressed in many solid tumors, and stable expression in HeLa cells confers resistance to doxorubicin and vincristine. In this study, we characterized stable transfectants of A2780 ovarian carcinoma cells. In a 3-day cytotoxicity assay, human SPF45 overexpression conferred 3- to 21-fold resistance to carboplatin, vinorelbine, doxorubicin, etoposide, mitoxantrone, and vincristine. In addition, resistance to gemcitabine and pemetrexed was observed at the highest drug concentrations tested. Knockdown of SPF45 in parental A2780 cells using a hammerhead ribozyme sensitized A2780 cells to etoposide by approximately 5-fold relative to a catalytically inactive ribozyme control and untransfected cells, suggesting a role for SPF45 in intrinsic resistance to some drugs. A2780-SPF45 cells accumulated similar levels of doxorubicin as vector-transfected and parental A2780 cells, indicating that drug resistance is not due to differences in drug accumulation. Efforts to identify small molecules that could block SPF45-mediated drug resistance revealed that the selective estrogen receptor (ER) modulators tamoxifen and LY117018 (a raloxifene analogue) partially reversed SPF45-mediated drug resistance to mitoxantrone in A2780-SPF45 cells from 21-fold to 8- and 5-fold, respectively, but did not significantly affect the mitoxantrone sensitivity of vector control cells. Quantitative PCR showed that ERbeta but not ERalpha was expressed in A2780 transfectants. Coimmunoprecipitation experiments suggest that SPF45 and ERbeta physically interact in vivo. Thus, SPF45-mediated drug resistance in A2780 cells may result in part from effects of SPF45 on the transcription or alternate splicing of ERbeta-regulated genes.


Cancer Research | 1998

Down-Regulation of the Novel Gene Melastatin Correlates with Potential for Melanoma Metastasis

Lyn M. Duncan; Jim Deeds; John Joseph Hunter; Jing Shao; Lisa Holmgren; Elizabeth A. Woolf; Robert I. Tepper; Andrew W. Shyjan


Genomics | 1998

Chromosomal localization and genomic characterization of the mouse melastatin gene (Mlsn1).

John Joseph Hunter; Jing Shao; John S. Smutko; Barry J. Dussault; Deborah L. Nagle; Elizabeth A. Woolf; Lisa M. Holmgren; Karen J. Moore; Andrew W. Shyjan


Archive | 1997

Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation

Andrew W. Shyjan


Archive | 1995

Murine gene fomy030 coding for tumor progression inhibitor

Andrew W. Shyjan


Archive | 1997

Compositions and methods for the diagnosis, prevention and treatment of tumor progression

Andrew W. Shyjan


Archive | 1998

Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer

Andrew W. Shyjan


Archive | 1999

METHODS AND COMPOSITIONS FOR THE IDENTIFICATION AND ASSESSMENT OF CANCER THERAPIES

Andrew W. Shyjan; Christophe Van Huffel


Archive | 2001

Methods and compositions for the identification, assessment, prevention and therapy of human cancers

Frederick P. Roth; Christophe Van Huffel; James V. White; Andrew W. Shyjan

Collaboration


Dive into the Andrew W. Shyjan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kyle J. Macbeth

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Grace H. W. Wong

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Shengfang Jin

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jing Shao

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

John Vassiliadis

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Mark Williamson

Millennium Pharmaceuticals

View shared research outputs
Researchain Logo
Decentralizing Knowledge